Suchergebnisse - "Papleux, Emmanuelle"

PubPharm (7)

1

Assessment 2 months after the administration of a 3rd dose mRNA : a new variant-adapted vaccine is expected

enthalten in: The Journal of infection | 2022

von Tré-Hardy, M. | Cupaiolo, R. | Wilmet, A. | +8

2

Azithromycin for treatment of hospitalised COVID-19 patients : a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)

enthalten in: ERJ open research | 2022

von Gyselinck, I. | Liesenborghs, L. | Belmans, A. | +20

3

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

enthalten in: The Journal of infection | 2021

von Tré-Hardy, M. | Cupaiolo, R. | Wilmet, A. | +7

CommentIn: J Infect. 2022 Jun;84(6):e118-e119. - PMID 35245580

4

An ectopic Cushing's syndrome as a cause of severe refractory hypokalemia in the ICU

enthalten in: Acta clinica Belgica | 2021

von Mohib, O. | Papleux, E. | Remmelink, M. | +2

5

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

enthalten in: The Journal of infection | 2021

von Tré-Hardy, M. | Cupaiolo, R. | Papleux, E. | +7

CommentOn: J Infect. 2021 May;82(5):162-169. - PMID 33766553

6

Direct antivirals working against the novel coronavirus : azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial

enthalten in: Trials | 2021

von Gyselinck, I. | Liesenborghs, L. | Landeloos, E. | +23

ErratumIn: Trials. 2021 Mar 5;22(1):187. - PMID 33673831

7

Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic

enthalten in: Pulmonary medicine | 2020

von Taton, O. | Papleux, E. | Bondue, B. | +8

1
[1]